• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
United Kingdom In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture - Product Image

United Kingdom In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

  • Published: December 2011
  • Region: United Kingdom, Great Britain
  • 247 pages
  • GlobalData

FEATURED COMPANIES

  • Abbott Laboratories
  • Atlas Medical
  • bioMerieux S.A.
  • DiaSorin S.p.A
  • Gen-Probe Incorporated
  • HORIBA, Ltd.
  • MORE

United Kingdom In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData’s new report, “United Kingdom In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the United Kingdom In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What is This Report About?
3 In Vitro Diagnostics In United Kingdom
3.1 In Vitro Diagnostics, Market Segmentation
3.2 In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017
3.3 In Vitro Diagnostics Market, United Kingdom, Revenue Mix ($m), 2010
3.4 In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2010
3.5 In Vitro Diagnostics, United Kingdom, Company share (2009-2010)
4 Clinical Chemistry In United Kingdom
4.1 Clinical Chemistry, Market Segmentation
4.2 Clinical Chemistry Market, United Kingdom, Revenue Mix ($m), 2010
4.3 Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2010
4.4 Clinical Chemistry Overall Revenue (2003-2017)
4.4.1 Clinical Chemisty Analyzers Revenue (2003-2017)
4.4.2 Urine Analysis Revenue (2003-2017)
4.5 Clinical Chemistry Distribution Share (2009-2010)
4.6 Clinical Chemistry, United Kingdom, Company share (2009-2010)
5 Genetic Testing In United Kingdom
5.1 Genetic Testing, Market Segmentation
5.2 Genetic Testing Market, United Kingdom, Revenue Mix ($m), 2010
5.3 Genetic Testing Market, United Kingdom, Segment Contribution (%), 2010
5.4 Genetic Testing Overall Revenue (2003-2017)
5.5 Genetic Testing Distribution Share (2009-2010)
5.6 Genetic Testing, United Kingdom, Company share (2009-2010)
6 Haematology In United Kingdom
6.1 Haematology, Market Segmentation
6.2 Haematology Market, United Kingdom, Revenue Mix ($m), 2010
6.3 Haematology Market, United Kingdom, Segment Contribution (%), 2010
6.4 Haematology Overall Revenue (2003-2017)
6.4.1 Haematology Reagents Revenue (2003-2017)
6.4.2 Immunohaematology Revenue (2003-2017)
6.4.3 Haemostasis Revenue (2003-2017)
6.4.4 Haematology Rapid Tests Revenue (2003-2017)
6.4.5 Haematology Cell Counters Revenue (2003-2017)
6.5 Haematology Distribution Share (2009-2010)
6.6 Haematology, United Kingdom, Company share (2009-2010)
7 Histology And Cytology In United Kingdom
7.1 Histology And Cytology, Market Segmentation
7.2 Histology And Cytology Market, United Kingdom, Revenue Mix ($m), 2010
7.3 Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2010
7.4 Histology And Cytology Overall Revenue (2003-2017)
7.5 Histology And Cytology Distribution Share (2009-2010)
7.6 Histology And Cytology, United Kingdom, Company share (2009-2010)
8 Immuno Chemistry In United Kingdom
8.1 Immuno Chemistry Market, United Kingdom, Revenue Mix ($m), 2010
8.2 Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2010
8.3 Immuno Chemistry Overall Revenue (2003-2017)
8.3.1 Disease Specific Immunochemistry Revenue (2003-2017)
8.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017)
8.3.3 Endocrinology Tests Revenue (2003-2017)
8.3.4 Therapeutic Drug Monitoring Revenue (2003-2017)
8.3.5 Immunochemistry Analyzers Revenue (2003-2017)
8.4 Immuno Chemistry Distribution Share (2009-2010)
8.5 Immuno Chemistry, United Kingdom, Company share (2009-2010)
9 Infectious Immunology In United Kingdom
9.1 Infectious Immunology, Market Segmentation
9.2 Infectious Immunology Market, United Kingdom, Revenue Mix ($m), 2010
9.3 Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2010
9.4 Infectious Immunology Overall Revenue (2003-2017)
9.5 Infectious Immunology Distribution Share (2009-2010)
9.6 Infectious Immunology, United Kingdom, Company share (2009-2010)
10 Microbiology Culture In United Kingdom
10.1 Microbiology Culture, Market Segmentation
10.2 Microbiology Culture Market, United Kingdom, Revenue Mix ($m), 2010
10.3 Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2010
10.4 Microbiology Culture Overall Revenue (2003-2017)
10.4.1 Microbiology Analyzers Revenue (2003-2017)
10.5 Microbiology Culture Distribution Share (2009-2010)
10.6 Microbiology Culture, United Kingdom, Company share (2009-2010)
11 Overview of Key Companies in United Kingdom In Vitro Diagnostics Market
11.1 Siemens Healthcare
11.1.1 Company Overview
11.1.2 Share in the United Kingdom In Vitro Diagnostics Market
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 Company Overview
11.2.2 Share in the United Kingdom In Vitro Diagnostics Market
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Share in the United Kingdom In Vitro Diagnostics Market
11.4 Beckman Coulter, Inc.
11.4.1 Company Overview
11.4.2 Share in the United Kingdom In Vitro Diagnostics Market
11.5 Sysmex Corporation
11.5.1 Company Overview
11.5.2 Share in the United Kingdom In Vitro Diagnostics Market
11.6 Ortho-Clinical Diagnostics Inc.
11.6.1 Company Overview
11.6.2 Share in the United Kingdom In Vitro Diagnostics Market
11.7 bioMerieux S.A.
11.7.1 Company Overview
11.8 Bio-Rad Laboratories, Inc.
11.8.1 Company Overview
11.9 Becton, Dickinson and Company
11.9.1 Company Overview
11.10 Alere Inc.
11.10.1 Company Overview
11.11 Phadia AB
11.11.1 Company Overview
11.12 DiaSorin S.p.A
11.12.1 Company Overview
11.13 Qiagen N.V.
11.13.1 Company Overview
11.14 Gen-Probe Incorporated
11.14.1 Company Overview
11.15 The Elitech Group
11.15.1 Company Overview
11.16 Atlas Medical
11.16.1 Company Overview
11.17 Thermo Fisher Scientific Inc.
11.17.1 Company Overview
11.18 HORIBA, Ltd.
11.18.1 Company Overview
11.19 PerkinElmer, Inc.
11.19.1 Company Overview
11.20 Hologic, Inc.
11.20.1 Company Overview
11.21 DIAGNOSTICA STAGO, Inc.
11.21.1 Company Overview
11.22 Life Technologies Corporation
11.22.1 Company Overview
12 In Vitro Diagnostics Market Pipeline Products
12.1 Clinical Chemisty Market Pipeline Products
12.2 Immuno Chemistry Market Pipeline Products
12.3 Haematology Market Pipeline Products
12.4 Infectious Immunology Market Pipeline Products
12.5 Microbiology Culture Market Pipeline Products
12.6 Histology And Cytology Market Pipeline Products
12.7 Genetic Testing Market Pipeline Products
13 Financial Deals Landscape
13.1 Merger
13.1.1 Centre For Molecular Medicine And Human Genetics Unit Merge To Form IGMM
13.2 Acquisition
13.2.1 Alere Receives Valid Acceptance For Revised Offer To Acquire Axis-Shield For $385 Million
13.2.2 Lab21 Acquires Myconostica
13.2.3 Techne Acquires Boston Biochem And Boston Biochem
13.2.4 Agilent Technologies Acquires Lab901
13.2.5 Imperial Innovations Acquires Minority Stake In Molecular Vision
13.2.6 Lab21 Acquires Microgen Bioproducts
13.3 Partnerships
13.3.1 Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals
13.3.2 Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics
13.3.3 Oxford Gene Technology Enters Into Co-Development Agreement With Abcodia
13.3.4 Horizon Discovery Enters Into Co-Development Agreement With Promega
13.3.5 Axis-Shield Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics
13.3.6 Generation Scotland Enters Into Co-Development Agreement With Arrayjet
13.3.7 Almac Group Enters Into Research Agreement With Queen’s University Belfast
13.3.8 Lumora Enters Into Licensing Agreement With 3M
13.3.9 BD Diagnostics Enters Into Co-Development Agreement With Lab21
13.3.10 Hycor Biomedical Signs Licensing Agreement With Axis-Shield
13.3.11 Proteome Sciences Enters Into Collaboration With Buck Institute
13.3.12 Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center
13.3.13 Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement
13.3.14 ResearchDx Enters Into Partnership With CompanDX
13.3.15 Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina
14 Recent Developments
14.1 Strategy and Business Planning
14.1.1 Sep 15, 2011: GE Healthcare To Invest $1 Billion in New Oncology R&D Solutions
14.1.2 Jul 21, 2011: Oxford Nanopore Expands Oxford Headquarters And Opens New Informatics Outstation In Cambridge, UK
14.1.3 Jun 28, 2011: Thermo Fisher And UK HPA Collaborate To Identify Toxicity Of New E. coli Strain
14.1.4 May 20, 2011: Almac Opens New North American Headquarters
14.1.5 May 19, 2011: Millipore Expands BioPharma CRO Services In Europe
14.1.6 Jan 20, 2011: Waters To Build New Mass Spectrometry Headquarters Near Manchester, UK
14.2 Legal and Regulatory
14.2.1 Nov 15, 2011: MonoSol Rx And Midatech Receive Authorization To Conduct Phase I Human Trials For Transbuccal Insulin PharmFilm
14.2.2 Aug 13, 2011: GE Healthcare And Bio-Rad Reach Settlement In Label-Free Detection Lawsuit
14.2.3 Jun 17, 2011: 3M Accused Of Breaking Promise To Market Life-Saving Medical Device Invented By British Government
14.2.4 Jan 10, 2011: Astellas To Review Strategic Business Alternatives For Prosidion Subsidiary
14.3 Government and Public Interest
14.3.1 Dec 19, 2011: NHS Publishes Implementation Guidelines For Source BioScience's Automated Cervical Cancer Screening Technology
14.3.2 Aug 22, 2011: Researchers Developing Blood Test To Improve Diagnosis Of Sickle Cell Disease In Babies: Action Medical
14.3.3 Jul 15, 2011: 'Swine Flu' Breath Test Could Reduce Future Vaccination Shortages, Research Suggests
14.3.4 Jul 12, 2011: CXR Biosciences And Taconic Announce Publication Of Drug-drug Interaction Study By Molecular Pharmacology Journal
14.3.5 Jun 27, 2011: University Of Leicester Study Into Use Of Blood Markers To Detect And Monitor Breast Cancer
14.3.6 Mar 25, 2011: NICE Pilot Diagnostics Project Points Way Forward For Evaluation Of Diagnostic Technologies
14.3.7 Mar 24, 2011: Oxford Immunotec: UK’s NICE Recommend Replacing Mantoux With TB Blood Tests For Key Patient Groups
14.3.8 Mar 17, 2011: Birmingham Scientists Create Test To Track Global Spread Of Antibiotic Resistance
14.3.9 Mar 02, 2011: New Way To Detect Prostate Cancer With New Urine Test: University Of Surrey Researchers
14.3.10 Mar 01, 2011: Gene Test To Predict Nerve Damage From Bone Cancer Treatment: Study
14.3.11 Feb 22, 2011: Peninsula Medical School Researchers Develop Home Urine Test Which Measures Insulin Production In Diabetes
14.3.12 Feb 11, 2011: Newcastle University Scientists Identify New Gene Test For Inherited Neuromuscular Disorder
14.3.13 Feb 09, 2011: Gene Test Could Solve Prostate Cancer Riddle And Spare Thousands From Surgery: UK Study
14.3.14 Feb 03, 2011: MRC Scientists Develop Blood Test For Variant Creutzfeldt-Jakob Disease
14.4 Product News
14.4.1 Dec 06, 2011: Trinity Biotech Receives FDA Approval For Premier Hb9210
14.4.2 Nov 23, 2011: Randox Toxicology Releases ELISA For Rapid Detection Of Synthetic Cannabinoids And Other Designer Drugs
14.4.3 Nov 15, 2011: Systagenix To Launch WOUNDCHEK Protease Status
14.4.4 Nov 09, 2011: Lab21 Announces Positive Results For MycAssayM Aspergillus Assay
14.4.5 Oct 05, 2011: Epistem Forms Human DNA Identification Collaboration With NPIA
14.4.6 Sep 01, 2011: CellaVision Delivers 1,000th CellaVision DM analyzer To Southampton General Hospital, England
14.4.7 Jul 18, 2011: Enigma Completes RANGER Project Based On Enigma ML-Influenza A/B
14.4.8 Jun 20, 2011: IntegenX Announces Early Access Partnership For RapidHIT 200 Human DNA Identification System
14.4.9 May 24, 2011: Studies Show Crescendo Bioscience’s Vectra DA Can Track Early Response To Rheumatoid Arthritis Therapy And Predict Joint Damage At Molecular Level
14.4.10 Apr 11, 2011: Enigma Announces Start Of US Clinical Trials For Influenza A/B Detection Assay
14.4.11 Apr 11, 2011: Enigma Announces Start Of US Clinical Trials For Influenza A/B Detection Assay
14.4.12 Apr 07, 2011: Myconostica Announces Publication Of Evaluation Of MycAssay Aspergillus Kit Performance
14.4.13 Apr 04, 2011: Myconostica Announces Publication Of Trial Results With MycAssay Pneumocystis Kit
14.4.14 Mar 22, 2011: Sphere Medical Receives FDA 510(k) Clearance For IVD-GE02 Blood Analyzer
14.4.15 Mar 22, 2011: Sphere Medical Receives FDA 510(k) Clearance For IVD-GE02 Blood Analyzer
14.4.16 Feb 28, 2011: Renishaw Diagnostics Launches RenDx RUO Multiplex Assay System
14.4.17 Feb 14, 2011: ValiRx Launches Chlamydia SELFCheck Over-The-Counter Health Screening Product
15 Appendix
15.1 Definitions of Markets Covered in the Report
15.1.1 In Vitro Diagnostics
15.2 Research Methodology
15.3 Secondary Research
15.4 Primary Research
15.5 Models
15.6 Forecasts
15.7 Expert Panels
15.8 GlobalData Consulting
15.9 Currency Conversion
15.10 Contact Us
15.11 Disclaimer

1.1 List of Tables
Table 1: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017
Table 2: In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2010
Table 3: In Vitro Diagnostics, United Kingdom, Cross-Category Analysis, 2003-2017
Table 4: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Table 5: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Table 6: In Vitro Diagnostics, United Kingdom, Company share by Revenue ($m), USD Actual, 2009-2010
Table 7: Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2010
Table 8: Clinical Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 9: Clinical Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 10: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 11: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 12: Urine Analysis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 13: Urine Analysis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 14: Clinical Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 15: Clinical Chemistry, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010
Table 16: Genetic Testing Market, United Kingdom, Segment Contribution (%), 2010
Table 17: Genetic Testing, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 18: Genetic Testing, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 19: Genetic Testing, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 20: Genetic Testing, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010
Table 21: Haematology Market, United Kingdom, Segment Contribution (%), 2010
Table 22: Haematology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 23: Haematology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 24: Haematology Reagents, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 25: Haematology Reagents, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 26: Immunohaematology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 27: Immunohaematology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 28: Haemostasis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 29: Haemostasis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 30: Haematology Rapid Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 31: Haematology Rapid Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 32: Haematology Cell Counters, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 33: Haematology Cell Counters, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 34: Haematology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 35: Haematology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010
Table 36: Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2010
Table 37: Histology And Cytology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 38: Histology And Cytology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 39: Histology And Cytology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 40: Histology And Cytology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010
Table 41: Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2010
Table 42: Immuno Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 43: Immuno Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 44: Disease Specific Immunochemistry, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 45: Disease Specific Immunochemistry, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 46: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 47: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 48: Endocrinology Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 49: Endocrinology Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 50: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 51: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 52: Immunochemistry Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 53: Immunochemistry Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 54: Immuno Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 55: Immuno Chemistry, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010
Table 56: Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2010
Table 57: Infectious Immunology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 58: Infectious Immunology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 59: Infectious Immunology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 60: Infectious Immunology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010
Table 61: Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2010
Table 62: Microbiology Culture, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 63: Microbiology Culture, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 64: Microbiology Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 65: Microbiology Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 66: Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 67: Microbiology Culture, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010
Table 68: Clinical Chemisty Market Pipeline Products
Table 69: Immuno Chemistry Market Pipeline Products
Table 70: Haematology Market Pipeline Products
Table 71: Infectious Immunology Market Pipeline Products
Table 72: Microbiology Culture Market Pipeline Products
Table 73: Histology And Cytology Market Pipeline Products
Table 74: Genetic Testing Market Pipeline Products
Table 75: Centre For Molecular Medicine And Human Genetics Unit Merge To Form IGMM
Table 76: Alere Receives Valid Acceptance For Revised Offer To Acquire Axis-Shield For $385 Million
Table 77: Lab21 Acquires Myconostica
Table 78: Techne Acquires Boston Biochem And Boston Biochem
Table 79: Agilent Technologies Acquires Lab901
Table 80: Imperial Innovations Acquires Minority Stake In Molecular Vision
Table 81: Lab21 Acquires Microgen Bioproducts
Table 82: Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals
Table 83: Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics
Table 84: Oxford Gene Technology Enters Into Co-Development Agreement With Abcodia
Table 85: Horizon Discovery Enters Into Co-Development Agreement With Promega
Table 86: Axis-Shield Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics
Table 87: Generation Scotland Enters Into Co-Development Agreement With Arrayjet
Table 88: Almac Group Enters Into Research Agreement With Queen’s University Belfast
Table 89: Lumora Enters Into Licensing Agreement With 3M
Table 90: BD Diagnostics Enters Into Co-Development Agreement With Lab21
Table 91: Hycor Biomedical Signs Licensing Agreement With Axis-Shield
Table 92: Proteome Sciences Enters Into Collaboration With Buck Institute
Table 93: Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center
Table 94: Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement
Table 95: ResearchDx Enters Into Partnership With CompanDX
Table 96: Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina
Table 97: USD to Local Currency, United Kingdom, Average Actual Rate 2003-2010

1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation
Figure 2: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017
Figure 3: In Vitro Diagnostics Market, United Kingdom, Revenue Mix ($m), 2010
Figure 4: In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2010
Figure 5: In Vitro Diagnostics, United Kingdom, Cross-Category Analysis, 2003-2017
Figure 6: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Figure 7: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Figure 8: In Vitro Diagnostics, United Kingdom, Company share (%), 2010
Figure 9: Clinical Chemistry, Market Segmentation
Figure 10: Clinical Chemistry Market, United Kingdom, Revenue Mix ($m), 2010
Figure 11: Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2010
Figure 12: Clinical Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 13: Clinical Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 14: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 15: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 16: Urine Analysis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 17: Urine Analysis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 18: Clinical Chemistry, United Kingdom, Company share (%), 2010
Figure 19: Genetic Testing, Market Segmentation
Figure 20: Genetic Testing Market, United Kingdom, Revenue Mix ($m), 2010
Figure 21: Genetic Testing Market, United Kingdom, Segment Contribution (%), 2010
Figure 22: Genetic Testing, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 23: Genetic Testing, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 24: Genetic Testing, United Kingdom, Company share (%), 2010
Figure 25: Haematology, Market Segmentation
Figure 26: Haematology Market, United Kingdom, Revenue Mix ($m), 2010
Figure 27: Haematology Market, United Kingdom, Segment Contribution (%), 2010
Figure 28: Haematology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 29: Haematology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 30: Haematology Reagents, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 31: Haematology Reagents, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 32: Immunohaematology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 33: Immunohaematology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 34: Haemostasis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 35: Haemostasis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 36: Haematology Rapid Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 37: Haematology Rapid Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 38: Haematology Cell Counters, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 39: Haematology Cell Counters, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 40: Haematology, United Kingdom, Company share (%), 2010
Figure 41: Histology And Cytology, Market Segmentation
Figure 42: Histology And Cytology Market, United Kingdom, Revenue Mix ($m), 2010
Figure 43: Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2010
Figure 44: Histology And Cytology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 45: Histology And Cytology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 46: Histology And Cytology, United Kingdom, Company share (%), 2010
Figure 47: Immuno Chemistry Market, United Kingdom, Revenue Mix ($m), 2010
Figure 48: Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2010
Figure 49: Immuno Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 50: Immuno Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 51: Disease Specific Immunochemistry, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 52: Disease Specific Immunochemistry, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 53: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 54: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 55: Endocrinology Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 56: Endocrinology Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 57: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 58: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 59: Immunochemistry Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 60: Immunochemistry Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 61: Immuno Chemistry, United Kingdom, Company share (%), 2010
Figure 62: Infectious Immunology, Market Segmentation
Figure 63: Infectious Immunology Market, United Kingdom, Revenue Mix ($m), 2010
Figure 64: Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2010
Figure 65: Infectious Immunology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 66: Infectious Immunology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 67: Infectious Immunology, United Kingdom, Company share (%), 2010
Figure 68: Microbiology Culture, Market Segmentation
Figure 69: Microbiology Culture Market, United Kingdom, Revenue Mix ($m), 2010
Figure 70: Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2010
Figure 71: Microbiology Culture, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 72: Microbiology Culture, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 73: Microbiology Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 74: Microbiology Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 75: Microbiology Culture, United Kingdom, Company share (%), 2010
Figure 76: Siemens Healthcare, Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010
Figure 77: F. Hoffmann-La Roche Ltd., Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010
Figure 78: Abbott Laboratories, Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010
Figure 79: Beckman Coulter, Inc., Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010
Figure 80: Sysmex Corporation, Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010
Figure 81: Ortho-Clinical Diagnostics Inc., Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010

Siemens Healthcare
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Beckman Coulter, Inc.
Sysmex Corporation
Ortho-Clinical Diagnostics Inc.
bioMerieux S.A.
Bio-Rad Laboratories, Inc.
Becton, Dickinson and Company
Alere Inc.
Phadia AB
DiaSorin S.p.A
Qiagen N.V.
Gen-Probe Incorporated
The Elitech Group
Atlas Medical
Thermo Fisher Scientific Inc.
HORIBA, Ltd.
PerkinElmer, Inc.
Hologic, Inc.
DIAGNOSTICA STAGO, Inc.
Life Technologies Corporation

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos